BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 06, 2004
 |  BioCentury  |  Product Development

Accelerated approval history

Accelerated approval history

Studies reviewed
Product Indication Approved Company (total patients) (A)
Arimidex anastrozole Adjuvant treatment for hormone receptor-positive early breast cancer 9/5/02 AstraZeneca 1 (9,366)
Bexxar tositumomab Non-Hodgkin's lymphoma (NHL) 6/27/03 Corixa 1 (60) (B)

Read the full 281 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >